Literature DB >> 2110799

Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids.

B K Gillard1, M A Jones, A A Turner, D E Lewis, D M Marcus.   

Abstract

Our previous work on human endothelial cell (EC) glycosphingolipids (GSLs) demonstrated that these cells contain a large diversity of GSLs, predominantly with lacto core structures. In order to evaluate the role of GSLs as EC antigens and receptors, we investigated their cell-surface expression on confluent EC monolayers and ECs activated by interferon-gamma (IFN-gamma) and interleukin-1 (IL-1). IFN-gamma activation of endothelial cells resulted in a small change in GSL composition, but greatly increased surface expression of gangliosides and decreased surface expression of neutral GSLs. In particular, surface expression of the major neutral GSL, globoside, decreased three- to fourfold as measured both by galactose oxidase labeling and by binding of the anti-globoside monoclonal antibody 9G7. IFN-gamma did not significantly alter the total cell content of globoside, as measured by metabolic labeling, but rather altered the ratio of accessible cell surface to intracellular globoside. Two mechanisms appear to contribute to the decreased cell-surface globoside expression. IFN-gamma treatment increased the relative proportion of intracellular globoside which is associated with the cell cytoskeleton. IFN-gamma treatment also caused more of the cell-surface globoside to be inaccessible to antibody, and both neuraminidase and trypsin treatment of the cells increased globoside accessibility. IL-1 treatment increased total cell GSL content, but did not alter GSL composition or cell-surface binding by six anti-carbohydrate antibodies. The specific modulation of cell-surface GSLs by IFN-gamma suggests that GSLs may play a role in the altered adhesive and receptor activities of IFN-gamma-activated ECs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110799     DOI: 10.1016/0003-9861(90)90471-a

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

Review 3.  Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.

Authors:  Andreas Bauwens; Josefine Betz; Iris Meisen; Björn Kemper; Helge Karch; Johannes Müthing
Journal:  Cell Mol Life Sci       Date:  2012-07-06       Impact factor: 9.261

4.  Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro.

Authors:  S A Kaye; C B Louise; B Boyd; C A Lingwood; T G Obrig
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

5.  Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues.

Authors:  J M Munro; S K Lo; C Corless; M J Robertson; N C Lee; R L Barnhill; D S Weinberg; M P Bevilacqua
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

6.  CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.

Authors:  M D Maloney; C A Lingwood
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

Review 7.  Glycoconjugates and related molecules in human vascular endothelial cells.

Authors:  Norihiko Sasaki; Masashi Toyoda
Journal:  Int J Vasc Med       Date:  2013-09-19

8.  My career as an immunoglycobiologist.

Authors:  Donald M Marcus
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2013       Impact factor: 3.493

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.